Mumefural

Modify Date: 2024-04-05 23:31:46

Mumefural structure	Common Name	Mumefural
	CAS Number	222973-44-6	Molecular Weight	300.22
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₂H₁₂O₉	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Mumefural

Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment[1][2].

Name	Mumefural

Description	Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR) Research Areas >> Cardiovascular Disease Research Areas >> Neurological Disease Signaling Pathways >> Cytoskeleton >> Integrin
Target	NF-κB TLR4 P-selectin E-selectin TNF-α
In Vivo	Mumefural (0.1-10 mg/kg; i.p.; once) 在大鼠中显示抗血栓作用[1]。 Mumefural (20-80 mg/kg; oral; daily for 42 days) 通过调节中隔海马胆碱能系统和神经炎症改善慢性脑灌注不足的认知障碍[2]。 Animal Model: SD rats, FeCl3-induced arterial thrombosis model[1] Dosage: 0.1, 1, or 10 mg/kg Administration: Intraperitoneal injection, 30 min before 35% FeCl3 treatment Result: Significantly improved blood flow by inhibiting occlusion and thrombus formation. Prevented collagen fiber damage in injured vessels and inhibited the expression of the platelet activation-related proteins P-selectin and E-selectin. Significantly reduced the increased inflammatory signal of nuclear factor (NF)-κB, toll-like receptor 4 (TLR4), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in blood vessels. Animal Model: Male Wistar rats, Chronic cerebral hypoperfusion (CCH) model[2] Dosage: 20, 40, or 80 mg/kg Administration: Oral, once a day for 42 days Result: Significantly improved cognitive impairment. Inhibited cholinergic system dysfunction, attenuated choline acetyltransferase-positive cholinergic neuron loss. Inhibited myelin basic protein degradation and increased the hippocampal expression of synaptic markers and cognition-related proteins. Reduced neuroinflammation, inhibited gliosis, and attenuated the activation of P2X7 receptor, TLR4/MyD88, NLRP3, and NF-κB. Animal Model: SD rats[1] Dosage: 2 or 10 mg/kg Administration: IV or PO (Pharmacokinetic Analysis) Result: Plasma pharmacokinetic parameters of Mumefural in SD rats[1] T1/2 (h) Tmax (h) Cmax (ng/mL) AUC0-t (ng⋅h/mL) F (%) IV (2 mg/kg) 0.14±0.05 0.08±0 1894.54±580.66 564.73±178.35 - PO (2 mg/kg) 0.69±0.69 0.31±0.13 1731.61±290.64 1043.28±202.37 36.95±7.17 AUC(0–t): area under the curve from the time of dosing to infinity; Cmax: maximum concentration; F: bioavailability; T1/2: terminal half-life; Tmax: time of the maximum concentration; SD: standard deviation; F was calculated using the following formula
References	[1]. Bang J, et al. Mumefural Improves Blood Flow in a Rat Model of FeCl3-Induced Arterial Thrombosis. Nutrients. 2020 Dec 10;12(12):3795. [2]. Bang J, et al. Mumefural Ameliorates Cognitive Impairment in Chronic Cerebral Hypoperfusion via Regulating the Septohippocampal Cholinergic System and Neuroinflammation. Nutrients. 2019 Nov 13;11(11):2755.

Molecular Formula	C₁₂H₁₂O₉
Molecular Weight	300.22